Literature DB >> 16907706

Geographical variations in TP53 mutational spectrum in ovarian carcinomas.

A Dansonka-Mieszkowska1, A H Ludwig, E Kraszewska, J Kupryjańczyk.   

Abstract

The TP53 gene mutational spectrum in human tumours shows variations related to tissue of origin, carcinogen exposure or molecular background. We have compared TP53 mutations in ovarian carcinomas from different geographical regions; this study was based on data extracted and verified from the IARC database (R10, 2005), and on our results from 127 carcinomas. In total 873 mutations were evaluated. Tumours from Japan and Korea had a higher frequency of exon 7 mutations (38%vs 25%, p = 0.011) and lower frequency of exon 8 mutations (11%vs 29%, p = 0.0003) than those from Western countries; they were particularly different from Norwegian tumours which showed the lowest proportion of exon 7 (19%, p = 0.001) and highest proportion of exon 8 (37%, p < 0.0001) mutations. There were also differences in the profile of TP53 hotspots. The third hotspot in tumours from Poland was amino acid (AA) 176 (8.2% of substitutions vs 1.7% in other countries, p < 0.001), while in tumours from the UK it was AA 220 (8.9%vs 2.3%, p < 0.001). Codon 273 was the only apparent hotspot in the Norwegian tumours, while it was rarely mutated in Polish and Asian tumours. In contrast to other data tumours from Norway presented with 273(HIS) codon (82% of mutations at AA 273, p = 0.002), while tumours from the UK shared the 273(CYS) codon (80%, p < 0.001). Further analysis of TP53 gene mutations in ovarian cancer by geography could provide greater insights.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16907706     DOI: 10.1111/j.1469-1809.2006.00257.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  14 in total

1.  p19(INK4d) mRNA and protein expression as new prognostic factors in ovarian cancer patients.

Authors:  Anna Felisiak-Golabek; Agnieszka Dansonka-Mieszkowska; Iwona K Rzepecka; Lukasz Szafron; Ewa Kwiatkowska; Bozena Konopka; Agnieszka Podgorska; Alina Rembiszewska; Jolanta Kupryjanczyk
Journal:  Cancer Biol Ther       Date:  2013-08-14       Impact factor: 4.742

2.  Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.

Authors:  Rajmohan Murali; Pier Selenica; David N Brown; R Keira Cheetham; Raghu Chandramohan; Nidia L Claros; Nancy Bouvier; Donavan T Cheng; Robert A Soslow; Britta Weigelt; W Glenn McCluggage
Journal:  Histopathology       Date:  2019-01-15       Impact factor: 5.087

3.  Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis.

Authors:  Abdul K Siraj; Tariq Masoodi; Rong Bu; Shaham Beg; Saif S Al-Sobhi; Fouad Al-Dayel; Mohammed Al-Dawish; Fowzan S Alkuraya; Khawla S Al-Kuraya
Journal:  Am J Hum Genet       Date:  2016-05-26       Impact factor: 11.025

4.  A novel germline PALB2 deletion in Polish breast and ovarian cancer patients.

Authors:  Agnieszka Dansonka-Mieszkowska; Anna Kluska; Joanna Moes; Michalina Dabrowska; Dorota Nowakowska; Anna Niwinska; Pawel Derlatka; Krzysztof Cendrowski; Jolanta Kupryjanczyk
Journal:  BMC Med Genet       Date:  2010-02-02       Impact factor: 2.103

5.  Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.

Authors:  Kuan-Ting Kuo; Bin Guan; Yuanjian Feng; Tsui-Lien Mao; Xu Chen; Natini Jinawath; Yue Wang; Robert J Kurman; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

6.  Histological profile and age at diagnosis of breast and ovarian tumors: A register-based study in Espirito Santo, Brazil.

Authors:  Eldamária DE Vargas Wolfgramm; Camila Fátima Biancardi Gavioli; Mayara Lemos Entringer; Lyvia Neves Rebello Alves; Elaine Stur; Allan Kardec DE Castro Neto; Luciene Lage DA Motta; Fausto Edmundo Lima Pereira; Iuri Drumond Louro
Journal:  Mol Clin Oncol       Date:  2012-11-05

7.  Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients.

Authors:  Anna Felisiak-Golabek; Alina Rembiszewska; Iwona K Rzepecka; Lukasz Szafron; Radoslaw Madry; Magdalena Murawska; Tomasz Napiorkowski; Piotr Sobiczewski; Beata Osuch; Jolanta Kupryjanczyk
Journal:  J Ovarian Res       Date:  2011-11-10       Impact factor: 4.234

8.  An identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers.

Authors:  E M Pinto; R C Ribeiro; J Li; L Taja-Chayeb; L F Carrasco; M de Lourdes Peña-Torres; S Vidal-Millán; H Maldonado-Mtz; A Dueñas-González; L McGregor; G P Zambetti
Journal:  Oncogenesis       Date:  2012-02-20       Impact factor: 7.485

9.  TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.

Authors:  Jolanta Kupryjanczyk; Ewa Kraszewska; Izabela Ziolkowska-Seta; Radoslaw Madry; Agnieszka Timorek; Janina Markowska; Jerzy Stelmachow; Mariusz Bidzinski
Journal:  BMC Cancer       Date:  2008-01-29       Impact factor: 4.430

10.  Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival.

Authors:  Katarzyna M Lisowska; Magdalena Olbryt; Sebastian Student; Katarzyna A Kujawa; Alexander J Cortez; Krzysztof Simek; Agnieszka Dansonka-Mieszkowska; Iwona K Rzepecka; Patrycja Tudrej; Jolanta Kupryjańczyk
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-30       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.